Jazz Pharmaceuticals Files 8-K on Financials
Ticker: JAZZ · Form: 8-K · Filed: May 1, 2024 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | 8-K |
| Filed Date | May 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: JAZZ
TL;DR
JAZZ filed an 8-K on May 1st detailing financial results. Check it out.
AI Summary
Jazz Pharmaceuticals plc filed an 8-K on May 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Dublin, Ireland.
Why It Matters
This 8-K filing provides investors with updated information on Jazz Pharmaceuticals' financial performance and operational results, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual risks or events.
Key Players & Entities
- Jazz Pharmaceuticals plc (company) — Registrant
- May 1, 2024 (date) — Date of Report
- Dublin, Ireland (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Jazz Pharmaceuticals plc's Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 1, 2024.
Where are Jazz Pharmaceuticals plc's principal executive offices located?
Jazz Pharmaceuticals plc's principal executive offices are located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.
What is the company's fiscal year end?
The company's fiscal year end is December 31 (1231).
What is the Standard Industrial Classification code for Jazz Pharmaceuticals plc?
The Standard Industrial Classification code for Jazz Pharmaceuticals plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-01 16:06:54
Key Financial Figures
- $0.0001 — stered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Marke
Filing Documents
- jazz-20240501.htm (8-K) — 28KB
- a1q24financialpr.htm (EX-99.1) — 385KB
- jazzpharma_logoxfullcolor.jpg (GRAPHIC) — 117KB
- 0001232524-24-000031.txt ( ) — 735KB
- jazz-20240501.xsd (EX-101.SCH) — 2KB
- jazz-20240501_lab.xml (EX-101.LAB) — 23KB
- jazz-20240501_pre.xml (EX-101.PRE) — 13KB
- jazz-20240501_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 1, 2024, Jazz Pharmaceuticals plc (the "Company") issued a press release (the "Press Release") announcing financial results for the Company for the quarter ended March 31, 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this current report. The information in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated May 1, 2024. 104 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Philip L. Johnson Name: Philip L. Johnson Title: Executive Vice President and Chief Financial Officer Date: May 1, 2024